CIK 0001104506 · Large accelerated filer
INSMED Inc
Sign in to watch- Ticker
- INSM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- VA
- Entity type
- operating
- EIN
- 541972729
- Phone
- 908-977-9900
- Business address
- 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,737,650
- in 2 filings
Net −$3,737,650. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-01 | Lewis William Chair and CEO | Sale 10b5-1 | −3,666 | $97.73 | $358K | 237,088 |
| 2025-07-01 | Lewis William Chair and CEO | Sale 10b5-1 | −2,349 | $98.83 | $232K | 234,739 |
| 2025-07-01 | Lewis William Chair and CEO | Sale 10b5-1 | −815 | $99.61 | $81K | 233,924 |
| 2025-07-01 | Lewis William Chair and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −6,830 | 20,525 | ||
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Option exercise 10b5-1 | +35,253 | $18.95 | $668K | 138,665 |
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Option exercise 10b5-1 | +12,636 | $19.74 | $249K | 151,301 |
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Sale 10b5-1 | −49,104 | $101.71 | $5.0M | 102,197 |
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Sale 10b5-1 | −8,661 | $102.15 | $885K | 93,536 |
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −35,253 | 99,007 | ||
| 2025-06-23 | Bonstein Sara Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −12,636 | 25,124 | ||
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −442 | $98.51 | $44K | 308,316 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −1,558 | $99.65 | $155K | 306,758 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −2,300 | $100.70 | $232K | 304,458 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −904 | $101.39 | $92K | 303,554 |
| 2025-06-16 | Lewis William Chair and CEO | Option exercise 10b5-1 | +129,805 | $10.85 | $1.4M | 363,729 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −7,000 | $98.50 | $690K | 356,729 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −32,490 | $99.51 | $3.2M | 324,239 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −48,531 | $100.54 | $4.9M | 275,708 |
| 2025-06-16 | Lewis William Chair and CEO | Sale 10b5-1 | −41,784 | $101.23 | $4.2M | 233,924 |
| 2025-06-16 | Lewis William Chair and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −129,805 | 27,355 |
Page 21 of 23 · 448 trades